Key Takeaways
- • OmicsBank secured $2.25 million in seed funding from Redesign Health, a global venture capital and technology firm, to expand clinical data infrastructure across U.S. health systems, pharmaceutical companies, biotechnology firms, CROs, and AI developers.
- • The company operates a clinical data platform that standardizes fragmented, unstructured hospital records into de-identified, patient-level datasets compliant with HIPAA, GDPR, and ISO 27001 standards, currently deployed across South Asia, Southeast Asia, and the Middle East.
- • OmicsBank's platform integrates structured EHR data, imaging, genomic, transcriptomic, proteomic, phenomic, and metabolomic datasets alongside biospecimens, enabling pharma companies and AI labs to access standardized data for drug discovery, development, and clinical AI applications.
- • Capital deployment will support geographic expansion into U.S. markets while scaling the clinical data network across Asia and the Middle East, addressing fragmentation in global healthcare data infrastructure.
Summary
OmicsBank, a clinical data infrastructure company, announced $2.25 million in seed funding from Redesign Health to accelerate expansion across the United States and international markets. The San Francisco-based company operates a platform that aggregates and standardizes fragmented clinical data from hospital and diagnostic networks, converting unstructured patient records into queryable, de-identified datasets suitable for pharmaceutical research, biotechnology development, and artificial intelligence applications.
The platform currently operates across South Asia, Southeast Asia, and the Middle East, serving pharmaceutical companies, contract research organizations, and frontier AI development labs. OmicsBank's data infrastructure spans multiple data modalities—including FHIR and OMOP CDM-structured electronic health records, medical imaging, genomic, transcriptomic, proteomic, phenomic, and metabolomic datasets, plus biospecimens. All datasets are made available through a process certified under ISO 27001 standards and compliant with HIPAA and GDPR regulations, with institutional review board and ethics committee approval.
The seed investment from Redesign Health will support two strategic initiatives: expansion across U.S. health systems, pharmaceutical companies, biotechnology firms, and CROs; and geographic scaling of the clinical data network into Asia and the Middle East. This funding positions OmicsBank to address a critical infrastructure gap in healthcare data standardization, where fragmented clinical records currently limit drug development efficiency and clinical AI deployment at scale.
The platform currently operates across South Asia, Southeast Asia, and the Middle East, serving pharmaceutical companies, contract research organizations, and frontier AI development labs. OmicsBank's data infrastructure spans multiple data modalities—including FHIR and OMOP CDM-structured electronic health records, medical imaging, genomic, transcriptomic, proteomic, phenomic, and metabolomic datasets, plus biospecimens. All datasets are made available through a process certified under ISO 27001 standards and compliant with HIPAA and GDPR regulations, with institutional review board and ethics committee approval.
The seed investment from Redesign Health will support two strategic initiatives: expansion across U.S. health systems, pharmaceutical companies, biotechnology firms, and CROs; and geographic scaling of the clinical data network into Asia and the Middle East. This funding positions OmicsBank to address a critical infrastructure gap in healthcare data standardization, where fragmented clinical records currently limit drug development efficiency and clinical AI deployment at scale.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.